RESET® Therapy: CE Mark Approval – Morphic Medical
RESET: A Non-surgical Option for Obesity and type 2 Diabetes
Table of Contents
Obesity and type 2 diabetes are significant health challenges affecting millions worldwide. If you’re seeking alternatives to conventional weight loss methods, you might be interested in a new approach: RESET, developed by Morphic Medical. This article will explore what RESET is, how it works, its potential benefits, and what the future holds for this innovative therapy.
Understanding the RESET Procedure
RESET (Revitalize, Endoscopically, Sustain, and Transform) is an endoscopically delivered therapy designed as a non-surgical treatment for morbid obesity and obesity-related cardiometabolic diseases like type 2 diabetes and dyslipidemia. Unlike invasive surgical procedures, RESET offers a less disruptive path toward weight management and improved health.
Here’s how it works:
Endoscopic Delivery: A specially designed liner is placed in the duodenum – the first part of the small intestine – using a standard endoscope. This is a minimally invasive procedure, typically performed as an outpatient visit.
Duodenal-Jejunal Bypass: The liner creates a temporary bypass of a portion of the small intestine. This alteration influences how your body absorbs nutrients and hormones,leading to changes in appetite and metabolism.
Improved Metabolic Health: By altering the gut’s hormonal signals,RESET can help improve blood sugar control,reduce cholesterol levels,and promote weight loss.
Temporary & Reversible: The liner remains in place for a defined period (currently up to 12 months) and is then removed, making the process reversible.
Real-World Outcomes and Clinical Evidence
The effectiveness of RESET is supported by growing clinical evidence. A study published in the British Journal of Diabetes (Ryder et al., 2022) showcased four-year outcomes from the first National Health Service (NHS) EndoBarrier service, demonstrating sustained benefits for patients with type 2 diabetes and obesity.
These benefits include:
Significant Weight Loss: Patients typically experience substantial weight loss, contributing to improved overall health.
Improved Glycemic Control: RESET has shown promise in helping individuals with type 2 diabetes achieve better blood sugar management, potentially reducing their reliance on medication.
Reduced Cardiometabolic Risk: The therapy can positively impact cholesterol levels and other cardiometabolic risk factors, lowering the risk of heart disease and stroke.
Enhanced Quality of Life: Many patients report improvements in their overall quality of life, including increased energy levels and improved mobility.
Who is a Candidate for RESET?
RESET is designed for individuals who:
Have a Body Mass Index (BMI) indicating obesity.
May have obesity alongside type 2 diabetes and/or dyslipidemia.
Are seeking a non-surgical choice to traditional weight loss procedures.
Have not achieved satisfactory results with diet and exercise alone.
It’s critically important to note that RESET is not currently approved for sale in the United States and is limited to investigational use only.
About morphic Medical: The Innovator Behind RESET
Morphic Medical, founded in 2003 and headquartered in Boston, Massachusetts, is the driving force behind RESET. The company is dedicated to developing innovative, endoscopically delivered therapies for obesity and related metabolic diseases.
You can learn more about Morphic Medical and RESET by visiting their website: https://morphicmedical.com/
Stay connected with Morphic Medical on social media:
Twitter: https://twitter.com/MorphicMedical
LinkedIn: https://www.linkedin.com/company/morphic-medical/?viewAsMember=true
The Future of RESET and Endoscopic Obesity Treatment
Morphic Medical continues to advance the field of endoscopic obesity treatment. ongoing research and